Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Trinity Biotech PLC

TRIB ✗ NOT COMPLIANTFree checks used up today ☆ Track — members

NASDAQ · Healthcare · Medical Equipment, Supplies & Distribution ·

USA Micro Cap Analyst: N/A

Last Close

$6.30

▼ -3.08%

Market Cap $5.09M · Vol 912

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$5.09M

Micro Cap

Div Yield

N/A

Annual dividend

EPS Growth

N/A

YoY

RSI (14)

47.07

Momentum

Beta

1.01

vs Market

52W High

$52.50

88.00% below

52W Low

$5.05

24.75% above

Volume

912

Avg 2.76K

P/B

N/A

Price-to-book

ROE

N/A

Return on equity

Free Float

86.23%

Public shares

Shariah Compliance8 STANDARDS

✗ Trinity Biotech PLC (TRIB) stock is currently not Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does TRIB pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-13.82%

-2.17%

-50.16%

-65.00%

YTD

-73.45%

-79.00%

-90.87%

-97.96%

Financials & Valuation

TTM · Annual

Total Revenue	$43.79M
Net Income	$-37,376,000.00
Revenue Growth (YoY)	+43.28%
Gross Margin	38.57%
Operating Margin	-26.07%
Net Profit Margin	-85.36%
ROE	N/A
ROA · ROIC	-35.67% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	0.34
P/B	N/A
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	16.26M

Technical Indicators

50-Day SMA	$7.65
200-Day SMA	$15.41
RSI (14)	47.07
Beta	1.01
52-Week High	$52.50
52-Week Low	$5.05

Volume Today	912
Avg Daily Volume (30D)	2.76K
Relative Volume	0.33x
Volatility (10D)	31.39
Volatility (30D)	116.35
Free Float	86.23%

Analyst Consensus

N/A

Current Price $6.30

Mean Target N/A

52W Low$5.05 52W High$52.50

Current

Target

$5.05 $52.50

Current Analyst target

· 0 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG001S67CN4

ISINUS8964386036

CountryIreland

Sub-IndustryLaboratory Diagnostic & Testing Substances

Earnings DateN/A

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

GH Guardant Health, Inc. -3.51% BIM.PA Biomerieux SA +0.39% CAI Caris Life Sciences, Inc. -5.01% TXG 10x Genomics, Inc. -14.03% 300832.SZ Shenzhen New Industries Biomedical Engineering Co Ltd +2.57%

Company Profile

Trinity Biotech plc is a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors. The Company develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Hemoglobin A1c and other chemical parameters in serum, plasma and whole blood, and the Company intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. Its TrinScreen Human Immunodeficiency Virus (HIV) rapid point-of-care test is a high-quality, single-use immunoassays to aid in the diagnosis of HIV. The Uni-Gold range of rapid point-of-care test devices consist of high-quality, single-use immunoassays to aid in the diagnosis of HIV.